Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sougakoff, W.
Right arrow Articles by Jarlier, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sougakoff, W.
Right arrow Articles by Jarlier, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 9-14
© 2000 The British Society for Antimicrobial Chemotherapy

Comparative potency of mecillinam and other ß-lactam antibiotics against Escherichia coli strains producing different ß-lactamases

W. Sougakoff* and V. Jarlier

Laboratoire de Recherche Moléculaire sur les Antibiotiques, Université Pierre et Marie Curie (Paris VI), Faculté de Médecine Pitié-Salpêtrière, 91 boulevard de l'hôpital, F-75634 Paris Cedex 13, France

The activity of mecillinam, a ß-lactam antibiotic with high affinity for Gram-negative penicillin-binding protein 2 (PBP2), was assessed against ampicillin-resistant Escherichia coli strains producing ß-lactamases representing the three molecular classes, A (TEM-1 and -3, SHV-3 and IRT-5), C (AmpC) and D (OXA-3). The antimicrobial activity of mecillinam and other ß-lactam antibiotics was evaluated by determining their MICs on Mueller–Hinton agar. The time course of hydrolysis in crude extracts prepared from the various ß-lactamase-producing strains was also measured and was used to determine the relative rate of hydrolysis and the apparent affinity for ampicillin, cephalothin and mecillinam. When compared with the other ß-lactam antibiotics, mecillinam demonstrated significantly greater antibacterial potency and higher stability to ß-lactamase hydrolysis in TEM-, IRT- and AmpC-producing isolates. These findings confirm that the antimicrobial potency of mecillinam compares favourably with those of the other penicillins included in the present study, suggesting that mecillinam use in the treatment of infections caused by Gram-negative bacteria should be re-evaluated.

* Corresponding author. Tel: +33-(0)1-40-77-97-46; Fax: +33-(0)1-45-82-75-77; E-mail: sougakof{at}lmcp.jussieu.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. C. Rodloff, E. J. C. Goldstein, and A. Torres
Two decades of imipenem therapy
J. Antimicrob. Chemother., November 1, 2006; 58(5): 916 - 929.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. P. Brenwald, J. Andrews, and A. P. Fraise
Activity of mecillinam against AmpC {beta}-lactamase-producing Escherichia coli
J. Antimicrob. Chemother., July 1, 2006; 58(1): 223 - 224.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. H. Mutnick, P. R. Rhomberg, H. S. Sader, and R. N. Jones
Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001)
J. Antimicrob. Chemother., February 1, 2004; 53(2): 290 - 296.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. Giamarellou
Prescribing guidelines for severe Pseudomonas infections
J. Antimicrob. Chemother., February 1, 2002; 49(2): 229 - 233.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.